Welcome to our dedicated page for OTIC news (Ticker: OTIC), a resource for investors and traders seeking the latest updates and insights on OTIC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OTIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OTIC's position in the market.
Otonomy, Inc. (Nasdaq: OTIC) will announce its first quarter 2022 financial results and corporate update on May 9, 2022, at 4:30 p.m. ET. Investors can participate in the live call by calling (877) 305-6769 or (678) 562-4239 for international access, using conference ID 5359095. A webcast of the event will be available on the company's investor relations website, archived for 30 days. Otonomy is focused on innovative therapeutics for neurotology, particularly addressing hearing loss and tinnitus through advanced drug delivery technology.
Otonomy, Inc. (Nasdaq: OTIC) announced positive results from the Phase 2a clinical trial of OTO-413 for hearing loss. A single intratympanic injection of 0.3 mg OTO-413 showed a clinically significant treatment benefit over placebo in multiple speech-in-noise tests at Days 57 and 85. Key findings include a 40% improvement rate in treated subjects compared to 20% for placebo. Otonomy plans to initiate a full dose-ranging Phase 2 efficacy trial by the end of 2022, with ongoing evaluations of higher doses expected to provide further insights.
Otonomy, a biopharmaceutical company focused on neurotology, will host a virtual Investor R&D Event on March 22, 2022, from 10 a.m. to Noon ET. The event will feature key opinion leaders discussing tinnitus and hearing loss along with positive results from the Phase 1/2 trials of Otonomy’s product candidates, OTO-313 and OTO-413. The senior management will also provide updates on ongoing clinical trials. Notable speakers include experts from Carnegie Mellon and the University of South Florida.
To register, visit the investor relations section of Otonomy's website.
Otonomy, Inc. (Nasdaq: OTIC) reported its financial results for 2021 and provided updates on its clinical pipeline. The company successfully fully enrolled its OTO-313 Phase 2 trial in tinnitus and OTO-413 Phase 2a cohort in hearing loss ahead of schedule. Top-line results for both trials are expected in mid-2022 and early second quarter of 2022, respectively. The company has $77.4 million in cash, sufficient to fund operations into the second half of 2023, while operating expenses are projected to be between $52-$54 million for 2022.
Otonomy, Inc. (Nasdaq: OTIC) announced its participation in virtual investor conferences, showcasing its commitment to innovative therapeutics for neurotology. Key events include:
- Cowen 42nd Annual Health Care Conference: “Auditory and Ophthalmology” panel on March 7, 2022, at 2:10 p.m. ET.
- Cowen 42nd Annual Health Care Conference: Fireside chat on March 8, 2022, at 1:30 p.m. ET.
- Oppenheimer 32nd Annual Healthcare Conference: Fireside chat on March 15, 2022, at 11:20 a.m. ET.
Live webcasts will be available on www.otonomy.com.
Otonomy, Inc. (NASDAQ: OTIC) will host a virtual Investor R&D Event on March 22, 2022, from 10 a.m. to Noon ET. This event will feature presentations by leading experts on tinnitus and hearing loss, as well as updates on the positive Phase 1/2 trial results for Otonomy’s OTO-313 and OTO-413 product candidates. Senior management will discuss ongoing clinical trials and future steps for these programs. Key speakers include notable researchers from Carnegie Mellon and the University of South Florida. Registration and webcast access are available on Otonomy’s investor relations website.
Otonomy, Inc. (NASDAQ: OTIC) announced the early completion of patient enrollment for the Phase 2 clinical trial of OTO-313, designed to treat tinnitus. This trial involved 153 patients, exceeding the target of 140, and aims to evaluate the efficacy of a single intratympanic injection of OTO-313 compared to placebo. Results are expected in mid-2022. Tinnitus affects approximately 10% of U.S. adults, and there are currently no FDA-approved drug treatments available.
Otonomy, Inc. (Nasdaq: OTIC) will announce its financial results for the fourth quarter and full year 2021 on February 28, 2022, at 4:30 p.m. ET. The company specializes in developing innovative therapeutics for neurotology, focusing on sustained drug delivery for conditions like hearing loss and tinnitus. Interested parties can join the live call by dialing the provided numbers or access a webcast on Otonomy's website. This event will include a corporate update on the company’s developments in the biopharmaceutical sector.
Otonomy, Inc. (Nasdaq: OTIC) announces two presentations on the OTO-413 hearing loss program at the 49th Annual Scientific and Technology Meeting of the AAS from February 24-26, 2022, in Scottsdale, Arizona. The presentations include results from the Phase 1/2 clinical trial of OTO-413 and a general review of the program. Key details include a podium presentation on February 24 by David R. Moore and an invited presentation on February 26 by Alan C. Foster, both focusing on innovations in hearing therapeutics.
Otonomy, Inc. (Nasdaq: OTIC) will present at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology in February 2022. Notable presentations include a workshop on inner ear therapies where Bonnie Jacques, Ph.D., will discuss intratympanic drug delivery.
Otonomy's poster presentations will feature critical research on OTO-825 gene therapy and its impact on hearing loss, alongside other collaborative studies focused on otoprotection and hair cell regeneration.
